Suggestions
Gemma Kelly
Laboratory Head at #WEHI - Expert in blood cancer research - #womeninSTEM
Associate Professor Gemma Kelly is a Laboratory Head within the Blood Cells and Blood Cancer Division at the Walter and Eliza Hall Institute of Medical Research (WEHI) and an NHMRC Leadership Fellow.12 Originally from the UK, she completed her undergraduate studies at Durham University and earned her PhD investigating virus-associated cancers at the Cancer Research UK (CRUK) Institute at The University of Birmingham.2
In 2009, Kelly relocated to Australia after receiving a Kay Kendall Leukemia Fund Fellowship.2 She established her own laboratory in 2019 within the Blood Cells and Blood Cancer Division at WEHI, headed by Andreas Strasser.2 Her research focuses on manipulating cell death pathways for cancer therapy, particularly in blood cancers.13
Kelly's team has made significant contributions to identifying resistance factors to BH3-mimetic drugs that directly induce apoptosis.2 Their recent work has centered on understanding deregulation of the p53 tumor suppressor pathways in therapy-resistant cancers and identifying new therapeutic approaches to enhance the efficacy of BH3-mimetic drugs for aggressive blood cancers.2
As of 2025, Kelly's laboratory is actively involved in cutting-edge research, using molecular and cellular biology techniques to identify vulnerabilities in leukemia and lymphoma cells that could be exploited for cancer therapy.1 Her team has expertise in various techniques, including CRISPR/Cas9-mediated genome editing, lentiviral production and transduction of cells, drug screening, and analysis of preclinical cancer models.1
Kelly has received numerous grants and awards throughout her career, including funding from the Cancer Council Victoria, Leukemia Foundation Australia, and the NHMRC.1 Her recent work has led to promising discoveries in combining venetoclax with STING agonists for the treatment of acute myeloid leukemia (AML), particularly in cases with p53 mutations.4

